183 related articles for article (PubMed ID: 30214621)
1. Comparative biodistribution analysis across four different
Bensch F; Smeenk MM; van Es SC; de Jong JR; Schröder CP; Oosting SF; Lub-de Hooge MN; Menke-van der Houven van Oordt CW; Brouwers AH; Boellaard R; de Vries EGE
Theranostics; 2018; 8(16):4295-4304. PubMed ID: 30214621
[No Abstract] [Full Text] [Related]
2.
Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
4. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
5. ImmunoPET imaging of tissue factor expression in pancreatic cancer with
Hernandez R; England CG; Yang Y; Valdovinos HF; Liu B; Wong HC; Barnhart TE; Cai W
J Control Release; 2017 Oct; 264():160-168. PubMed ID: 28843831
[TBL] [Abstract][Full Text] [Related]
6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
Perk LR; Visser OJ; Stigter-van Walsum M; Vosjan MJ; Visser GW; Zijlstra JM; Huijgens PC; van Dongen GA
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1337-45. PubMed ID: 16832633
[TBL] [Abstract][Full Text] [Related]
8. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
11. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
[TBL] [Abstract][Full Text] [Related]
12. Molecular Imaging of a Zirconium-89 Labeled Antibody Targeting Plasmodium falciparum-Infected Human Erythrocytes.
Duvenhage J; Ebenhan T; Garny S; Hernández González I; Leyva Montaña R; Price R; Birkholtz LM; Zeevaart JR
Mol Imaging Biol; 2020 Feb; 22(1):115-123. PubMed ID: 31004274
[TBL] [Abstract][Full Text] [Related]
13. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
[TBL] [Abstract][Full Text] [Related]
15. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
16. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
[TBL] [Abstract][Full Text] [Related]
17. Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.
Jauw YWS; Heijtel DF; Zijlstra JM; Hoekstra OS; de Vet HCW; Vugts DJ; Verheul HM; Boellaard R; Zweegman S; van Dongen GAMS; der Houven van Oordt CWM; Lammertsma AA; Huisman MC
Mol Imaging Biol; 2018 Dec; 20(6):1025-1034. PubMed ID: 29713958
[TBL] [Abstract][Full Text] [Related]
18. Molecular Drug Imaging:
Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
[TBL] [Abstract][Full Text] [Related]
19.
Bensch F; Lamberts LE; Smeenk MM; Jorritsma-Smit A; Lub-de Hooge MN; Terwisscha van Scheltinga AGT; de Jong JR; Gietema JA; Schröder CP; Thomas M; Jacob W; Abiraj K; Adessi C; Meneses-Lorente G; James I; Weisser M; Brouwers AH; de Vries EGE
Clin Cancer Res; 2017 Oct; 23(20):6128-6137. PubMed ID: 28733442
[No Abstract] [Full Text] [Related]
20. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
